Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Making Strides To Fill Future Lipitor Gap

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer demonstrates its "balanced portfolio" approach, with five recent deals, but concerns linger about its ability to meet its 2012 financial targets .

You may also be interested in...



Deals Of The Week: Valeant/Eyetech, Merck/Supera Farma, Merck/Zhifei

Biogen’s purchase of Stromedix completes the buy-up of independently held biotech assets in the furious competition to take the lead in idiopathic pulmonary fibrosis.

Sanofi Growth Slows In Emerging Markets But South America Accelerates: Emerging Markets Earnings Round Up (Part 2)

Patent Cliff Leads Pfizer To Begin Direct Sales To Pharmacies; Aussie Distributors Reeling

SINGAPORE - Pfizer Australia will begin direct sales of its prescription medicines to pharmacies in early 2011, cutting out distributors as part of a global battle to go head-to-head against generic copies of blockbuster drugs like Lipitor that face patent expiry in the coming years

Related Content

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel